[Advanced Enteric-type Thymic Adenocarcinoma with Axillary Lymph Node Oligometastasis: A Case Report].
- 1Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
- 2Department of Pathology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Abstract
Enteric‑type thymic adenocarcinoma (ETAC) is a rare subtype of thymic carcinoma. It shares highly similar histological and immunophenotypic features with intestinal adenocarcinoma, and is therefore prone to being misdiagnosed as metastatic carcinoma of gastrointestinal origin. Herein, we report a case of advanced ETAC with axillary lymph node oligometastasis. Positron emission tomography/computed tomography (PET/CT) and gastrointestinal endoscopy were performed to rule out primary gastrointestinal malignancy. The patient underwent median sternotomy with extended thymectomy, which effectively relieved superior vena cava obstruction and cardiopulmonary compressive symptoms. Postoperatively, systemic chemotherapy combined with immunotherapy, as well as regional radiotherapy targeting the primary tumor bed and metastatic lymph nodes, were administered. The patient remained disease‑free during the 24‑month postoperative follow‑up. This case suggests that aggressive local therapy combined with molecular‑subtype‑based systemic treatment may offer novel therapeutic opportunities for carefully selected patients with advanced ETAC and oligometastases. .
Related
- Relative change rate of neutrophil-to-albumin ratio (ΔNAR) during neoadjuvant chemotherapy predicts axillary pathological complete response in locally advanced breast cancer
- Efficacy and Safety of Lucitanib in Advanced Thymic Carcinoma: A Randomized Phase II Trial.
- Pulmonary Enteric Adenocarcinoma: From Diagnostic Attribution and Molecular Biology to Biomarker-Guided Clinical Pharmacology
- Primary enteric-type adenocarcinoma of the renal parenchyma in a patient with bilateral renal malrotation: a case report and review of the literature
- First-line toripalimab in combination with platinum-doublet chemotherapy for advanced B3 thymoma and thymic carcinoma: an open-label prospective phase Ⅱ trial.
BibTeX
@article{huang2026advanced,
title = {{[Advanced Enteric-type Thymic Adenocarcinoma with Axillary Lymph Node Oligometastasis: A Case Report].}},
author = {Chuan Huang and Zheng Wang and Hongfeng Tong},
journal = {Zhongguo fei ai za zhi = Chinese journal of lung cancer},
year = {2026},
month = aug,
doi = {10.3779/j.issn.1009-3419.2026.101.18},
url = {https://europepmc.org/article/MED/42896977},
note = {CC BY},
}
RIS
TY - JOUR
TI - [Advanced Enteric-type Thymic Adenocarcinoma with Axillary Lymph Node Oligometastasis: A Case Report].
AU - Chuan Huang
AU - Zheng Wang
AU - Hongfeng Tong
PY - 2026
DA - 2026/08/01
JO - Zhongguo fei ai za zhi = Chinese journal of lung cancer
DO - 10.3779/j.issn.1009-3419.2026.101.18
UR - https://europepmc.org/article/MED/42896977
AB - Enteric‑type thymic adenocarcinoma (ETAC) is a rare subtype of thymic carcinoma. It shares highly similar histological and immunophenotypic features with intestinal adenocarcinoma, and is therefore prone to being misdiagnosed as metastatic carcinoma of gastrointestinal origin. Herein, we report a case of advanced ETAC with axillary lymph node oligometastasis. Positron emission tomography/computed tomography (PET/CT) and gastrointestinal endoscopy were performed to rule out primary gastrointestinal malignancy. The patient underwent median sternotomy with extended thymectomy, which effectively relieved superior vena cava obstruction and cardiopulmonary compressive symptoms. Postoperatively, systemic chemotherapy combined with immunotherapy, as well as regional radiotherapy targeting the primary tumor bed and metastatic lymph nodes, were administered. The patient remained disease‑free during the 24‑month postoperative follow‑up. This case suggests that aggressive local therapy combined with molecular‑subtype‑based systemic treatment may offer novel therapeutic opportunities for carefully selected patients with advanced ETAC and oligometastases. .
SN - 1009-3419
SN - 1999-6187
ER -